FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000945717> ?p ?o ?g. }

• W2000945717 endingPage "3" @default.
• W2000945717 startingPage "1" @default.
• W2000945717 abstract "Hepatocellular carcinoma (HCC) is one of the most common health threats worldwide. HCC is characterized by silent development and poor prognosis as well as 5-year survival rates of 5 %. The incidence and mortality rates of HCC are increasing in many countries, especially in Asian populations. The major risk factors for HCC development are hepatitis B and C viral infections, which contribute to 75 % of HCC cases. Other etiological factors, such as alcohol consumption, aflatoxin, obesity and diabetes, are also frequently observed in clinics [1, 2]. According to practice guidelines, treatment options include surgical resection, liver transplantation, percutaneous ablation, transarterial chemoembolization (TACE) and percutaneous ethanol injection, which are selected by hepatologists based on staging of primary HCC. In the early stage, surgical resection remains the most effective treatment with 40–70 % 5-year survival rates; however, only 10–20 % of the subjects with HCC are eligible for surgical resection because of poorly preserved liver function, portal vein invasion or extrahepatic spread [3]. TACE is recommended as the first-line treatment for HCC patients with intermediate stage disease and for downstaging tumors that exceed the criteria for transplantation [1]. One randomized trial evaluated the survival benefit with TACE and found that TACE-treated patients had a prolonged 2-year survival of 63 % compared with 27 % with only a supportive care [4]. Transarterial radioembolization (TARE) is based on the injection of radiolabeled particles through the hepatic artery into the in situ tumor and has become another option for patients with intermediate-stage HCC in recent years [5]. A long-term follow-up check study demonstrated that TARE was well tolerated, with significantly lower rates of abdominal pain and elevated liver enzymes, but median survival was not significantly increased compared with TACE-treated patients [6]. Although improvements have been made in the treatment of HCC, the incidence and mortality rates of HCC are still increasing. This may be partially accounted for by the fact that most HCC patients are diagnosed at advanced stages [5]. Unfortunately, the available therapies for patients with advanced HCC are extremely limited. Sorafenib is a new multi-target drug that blocks tumor angiogenesis and proliferation by inhibiting the components of the Raf signaling pathway [7]. The safety and efficacy of sorafenib in the treatment of advanced HCC has been demonstrated in some recent clinical trials [8–11]. It improved the median survival time by *3 months (the median for sorafenib was 10.7 months, while the median for the placebo group was 7.9 months) in patients with advanced HCC [10]. However, there is still a lack of significant treatment efficacy according to the response evaluation criteria in solid tumors (RECIST) [3]. In addition, the application of sorafenib was limited because of severe adverse events, including skin rash, hand-foot skin reactions, diarrhea and hypertension. Other potential treatments for advanced HCC, such as gene therapy and immunotherapy, are still under investigation and may be accepted as adjuvant therapies. Therefore, it is of great interest to develop more effective and practical therapeutic strategies for advanced HCC patients. Tamibarotene (4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl2-naphthyl] carbamoyl benzoic acid) is a synthetic retinoid that selectively binds to retinoic acid receptors [12]. Compared to all-trans retinoic acid, tamibarotene is chemically J. Fu J.-Y. Zhang F.-S. Wang (&) Research Center for Biological Therapy, Beijing 302 Hospital, Institute of Translational Hepatology, Beijing 100039, People’s Republic of China e-mail: fswang302@163.com" @default.
• W2000945717 created "2016-06-24" @default.
• W2000945717 creator A5042360471 @default.
• W2000945717 creator A5044804183 @default.
• W2000945717 creator A5051162009 @default.
• W2000945717 date "2013-12-28" @default.
• W2000945717 modified "2023-09-27" @default.
• W2000945717 title "Tamibarotene: a new hope for therapeutic efficacy in hepatocellular carcinoma patients" @default.
• W2000945717 cites W1553842589 @default.
• W2000945717 cites W1971837077 @default.
• W2000945717 cites W1994193851 @default.
• W2000945717 cites W2001414794 @default.
• W2000945717 cites W2025129086 @default.
• W2000945717 cites W2040183552 @default.
• W2000945717 cites W2058887247 @default.
• W2000945717 cites W2064435248 @default.
• W2000945717 cites W2089812753 @default.
• W2000945717 cites W2121367471 @default.
• W2000945717 cites W2125763116 @default.
• W2000945717 cites W2128125049 @default.
• W2000945717 cites W2141247830 @default.
• W2000945717 cites W2141500327 @default.
• W2000945717 cites W2152899866 @default.
• W2000945717 cites W2156871508 @default.
• W2000945717 cites W2171365151 @default.
• W2000945717 cites W4245499753 @default.
• W2000945717 cites W4255312897 @default.
• W2000945717 cites W2084018413 @default.
• W2000945717 doi "https://doi.org/10.1007/s12072-013-9493-5" @default.
• W2000945717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26202399" @default.
• W2000945717 hasPublicationYear "2013" @default.
• W2000945717 type Work @default.
• W2000945717 sameAs 2000945717 @default.
• W2000945717 citedByCount "3" @default.
• W2000945717 countsByYear W20009457172017 @default.
• W2000945717 countsByYear W20009457172020 @default.
• W2000945717 crossrefType "journal-article" @default.
• W2000945717 hasAuthorship W2000945717A5042360471 @default.
• W2000945717 hasAuthorship W2000945717A5044804183 @default.
• W2000945717 hasAuthorship W2000945717A5051162009 @default.
• W2000945717 hasBestOaLocation W20009457171 @default.
• W2000945717 hasConcept C126322002 @default.
• W2000945717 hasConcept C143998085 @default.
• W2000945717 hasConcept C177713679 @default.
• W2000945717 hasConcept C2778019345 @default.
• W2000945717 hasConcept C2780120127 @default.
• W2000945717 hasConcept C2780140570 @default.
• W2000945717 hasConcept C41260117 @default.
• W2000945717 hasConcept C523026621 @default.
• W2000945717 hasConcept C61434518 @default.
• W2000945717 hasConcept C71924100 @default.
• W2000945717 hasConcept C90924648 @default.
• W2000945717 hasConceptScore W2000945717C126322002 @default.
• W2000945717 hasConceptScore W2000945717C143998085 @default.
• W2000945717 hasConceptScore W2000945717C177713679 @default.
• W2000945717 hasConceptScore W2000945717C2778019345 @default.
• W2000945717 hasConceptScore W2000945717C2780120127 @default.
• W2000945717 hasConceptScore W2000945717C2780140570 @default.
• W2000945717 hasConceptScore W2000945717C41260117 @default.
• W2000945717 hasConceptScore W2000945717C523026621 @default.
• W2000945717 hasConceptScore W2000945717C61434518 @default.
• W2000945717 hasConceptScore W2000945717C71924100 @default.
• W2000945717 hasConceptScore W2000945717C90924648 @default.
• W2000945717 hasIssue "1" @default.
• W2000945717 hasLocation W20009457171 @default.
• W2000945717 hasLocation W20009457172 @default.
• W2000945717 hasOpenAccess W2000945717 @default.
• W2000945717 hasPrimaryLocation W20009457171 @default.
• W2000945717 hasRelatedWork W132580302 @default.
• W2000945717 hasRelatedWork W141702278 @default.
• W2000945717 hasRelatedWork W168719843 @default.
• W2000945717 hasRelatedWork W201071328 @default.
• W2000945717 hasRelatedWork W2046482740 @default.
• W2000945717 hasRelatedWork W2598100848 @default.
• W2000945717 hasRelatedWork W2603048310 @default.
• W2000945717 hasRelatedWork W354276327 @default.
• W2000945717 hasRelatedWork W367043394 @default.
• W2000945717 hasRelatedWork W80103391 @default.
• W2000945717 hasVolume "8" @default.
• W2000945717 isParatext "false" @default.
• W2000945717 isRetracted "false" @default.
• W2000945717 magId "2000945717" @default.
• W2000945717 workType "article" @default.